Corona pill that 'halves the chances of hospitalization or death

Pharmaceutical company Merck says its experimental pill has halved the chances of hospitalization or death for people with COD 19, a key step in the global fight against coronavirus.

According to the Associated Press (AP), the drug will be the first pill of its kind to treat cod, which will become part of a pre-existing drug that has already been vaccinated, according to the Associated Press (AP). Are in shape.

Merck says it will soon ask health officials in the United States and around the world to approve the use of the pill.

A decision by the US Food and Drug Administration could be made within weeks of the request. If the pill is approved, the pill will be distributed immediately.

All types of Code 19 treatment in the United States currently require vaccines or drips. On the contrary, taking the pill at home will help reduce the pressure on hospitals and prevent the spread of the epidemic in poor and remote areas of the world where access to expensive vaccine treatments is not available.

Dr. William Schiffenrum, an epidemiologist at Vanderbilt University in the United States, who was not involved in the study, said: "This will allow us to treat more people more quickly. We are confident that it will be cheaper. "

Merck and its partner company, Rageback Biotherapy, say preliminary results indicate that people who take an antiviral pill called molonoperavir within five days of developing cod symptoms are more likely to be hospitalized and die. Half were compared to those who were given a dummy or a placebo shot.

One study looked at 775 adults who had mild to moderate symptoms of codeine 19. These people were considered to be at high risk of developing a serious illness due to obesity, diabetes and heart disease.

External experts have not yet reviewed the findings, which is the norm in any new medical research.

According to Merck, 7.3% of those who received molonovirus were hospitalized or died at the end of 30 days. This compares with the 14.1% of people who received a dummy shot. After this period, eight of the dummy drug users succumbed to the disease while there were no deaths compared to those who were given molonoperavir.

The results were so excellent that an independent group of medical experts overseeing the trial use of the pill recommended that the clinical trial be terminated prematurely. Top Merck officials say they plan to submit test data to the FDA in the coming days.